Chemomab Therapeutics Ltd.
NASDAQ Capital MarketTotal Valuation
Chemomab Therapeutics Ltd. carries a market capitalization of 7.20M, placing it among publicly traded companies globally. Its enterprise value stands at 942.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.20M |
| Enterprise Value | 942.98M |
Share Statistics
Chemomab Therapeutics Ltd. currently has 586.21M shares outstanding.
| Shares Outstanding | 586.21M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 109.35 |
| P/TBV Ratio | 109.35 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Chemomab Therapeutics Ltd. maintains a current ratio of 6.41, meaning it holds 6.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.41 |
| Quick Ratio | 6.41 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -82.17 |
| Return on Assets (ROA) | -70.70 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Chemomab Therapeutics Ltd.'s stock has declined approximately -65.58824% over the past 52 weeks. The 50-day moving average sits at 2.05, while the 200-day moving average is 1.79.
| Beta (5Y) | N/A |
| 52-Week Price Change | -65.58824% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 1.79 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -7.91M, while operating income came in at -7.91M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -7.91M |
| Pretax Income | -7.55M |
| Net Income | -7.55M |
| EBITDA | -7.91M |
| EBIT | -7.91M |
| Earnings Per Share (EPS) | -1.09 |
Balance Sheet
Total book value stands at 8.69M, with working capital of 8.40M providing operational flexibility.
| Cash & Cash Equivalents | 6.69M |
| Total Debt | N/A |
| Net Debt | -6.00M |
| Equity (Book Value) | 8.69M |
| Book Value Per Share | 0.01 |
| Working Capital | 8.40M |
Stock Splits
Chemomab Therapeutics Ltd.'s most recent stock split took place on August 26, 2025 with a 4:1 split ratio.
| Last Split Date | 8/26/2025 |
| Split Ratio | 4:1 |
Scores
Chemomab Therapeutics Ltd. posts an Altman Z-Score of 349.54, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 349.54 |